menu
    • menu

    Find Daclatasvir manufacturers, exporters & distributors on PharmaCompass

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass

    Synopsis

    Related ProductsRelated Products

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    28

    API Suppliers

    API Suppliers

    5

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    6

    EU WC

    EU WC

    0

    KDMF

    KDMF

    5

    NDC API

    NDC API

    0

    VMF

    NDC API

    22

    Listed Suppliers

    Other Suppliers

    API REF. PRICE (USD/KG)

    $
    $ 654

    MARKET PLACE

    7

    API

    0

    FDF

    9INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    12

    FDF Dossiers

    FDF Dossiers

    3

    FDA Orange Book

    FDA (Orange Book)

    6

    Europe

    Europe

    0

    Canada

    Canada

    0

    Australia

    Australia

    0

    South Africa

    South Africa

    3

    Listed Dossiers

    Listed Dossiers

    0 DRUGS IN DEVELOPMENT

    FDF DossiersDRUG PRODUCT COMPOSITIONS

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    0

    Others

    PATENTS & EXCLUSIVITIES

    18

    US Patents

    0

    US Exclusivities

    4

    Health Canada Patents

    DIGITAL CONTENT

    3

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    44

    News #PharmaBuzz

    GLOBAL SALES INFORMATION

    US Medicaid

    NA

    Annual Reports

    2,257

    Finished Drug Prices

    Listed Dossiers

    129 RELATED EXCIPIENT COMPANIES

    215EXCIPIENTS BY APPLICATIONS

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 1009119-64-5, Daclatasvir (bms-790052), Bms-790052, Daklinza, 1214735-16-6, Ebp 883
    Molecular Formula
    C40H50N8O6
    Molecular Weight
    738.9  g/mol
    InChI Key
    FKRSSPOQAMALKA-CUPIEXAXSA-N
    FDA UNII
    LI2427F9CI
    Daclatasvir
    Daclatasvir is an orally available inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A) replication complex, with potential activity against HCV. Although the exact mechanism of action of daclatasvir has yet to be fully determined, this agent, upon oral administration and after intracellular uptake, appears to bind to domain I of the NS5A protein. This inhibits the activity of the NS5A protein and results in the disruption of the viral RNA replication complex, blockage of viral HCV RNA production, and inhibition of viral replication. NS5A, a zinc-binding and proline-rich hydrophilic phosphoprotein, plays a crucial role in HCV RNA replication. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family.
    Daclatasvir is a Hepatitis C Virus NS5A Inhibitor. The mechanism of action of daclatasvir is as a P-Glycoprotein Inhibitor, and Organic Anion Transporting Polypeptide 1B1 Inhibitor, and Organic Anion Transporting Polypeptide 1B3 Inhibitor, and Breast Cancer Resistance Protein Inhibitor.
    1 2D Structure

    Daclatasvir

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    methyl N-[(2S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
    2.1.2 InChI
    InChI=1S/C40H50N8O6/c1-23(2)33(45-39(51)53-5)37(49)47-19-7-9-31(47)35-41-21-29(43-35)27-15-11-25(12-16-27)26-13-17-28(18-14-26)30-22-42-36(44-30)32-10-8-20-48(32)38(50)34(24(3)4)46-40(52)54-6/h11-18,21-24,31-34H,7-10,19-20H2,1-6H3,(H,41,43)(H,42,44)(H,45,51)(H,46,52)/t31-,32-,33-,34-/m0/s1
    2.1.3 InChI Key
    FKRSSPOQAMALKA-CUPIEXAXSA-N
    2.1.4 Canonical SMILES
    CC(C)C(C(=O)N1CCCC1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)C6CCCN6C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC
    2.1.5 Isomeric SMILES
    CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC
    2.2 Other Identifiers
    2.2.1 UNII
    LI2427F9CI
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Bms-790052

    2. Bms-790052-05

    3. Carbamic Acid, N,n'-((1,1'-biphenyl)-4,4'-diylbis(1h-imidazole-5,2-diyl-(2s)-2,1-pyrrolidinediyl((1s)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl)))bis-, C,c'-dimethyl Ester

    4. Daclatasvir Dihydrochloride

    5. Daklinza

    2.3.2 Depositor-Supplied Synonyms

    1. 1009119-64-5

    2. Daclatasvir (bms-790052)

    3. Bms-790052

    4. Daklinza

    5. 1214735-16-6

    6. Ebp 883

    7. Bms790052

    8. Bms 790052

    9. Daclatasvir [usan]

    10. Methyl N-[(2s)-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2s)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate

    11. Chebi:82977

    12. Ebp-883

    13. Daclatasvir (usan)

    14. Carbamic Acid, N,n'-[[1,1'-biphenyl]-4,4'-diylbis[1h-imidazole-5,2-diyl-(2s)-2,1-pyrrolidinediyl[(1s)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis-, C,c'-dimethyl Ester

    15. Carbamic Acid, N,n'-((1,1'-biphenyl)-4,4'-diylbis(1h-imidazole-5,2-diyl-(2s)-2,1-pyrrolidinediyl((1s)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl)))bis-, C,c'-dimethyl Ester

    16. Dimethyl ((2s,2's)-((2s,2's)-2,2'-(5,5'-([1,1'-biphenyl]-4,4'-diyl)bis(1h-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl))dica

    17. 1009119-65-6

    18. Li2427f9ci

    19. Methyl N-[(1s)-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2s)-2-(methoxycarbonylamino)-3-methyl-butanoyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidine-1-carbonyl]-2-methyl-propyl]carbamate

    20. Daclatasvir [mi]

    21. Daclatasvir [inn]

    22. Daclatasvir [who-dd]

    23. Dimethyl (2s,2's)-1,1'-((2s,2's)-2,2'-(4,4'-(biphenyl-4,4'-diyl)bis(1h-imidazole-4,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl)dicarbamate

    24. Mls006011140

    25. Ebp883

    26. Schembl2756027

    27. Chembl2023898

    28. Schembl17897804

    29. Gtpl11266

    30. Ex-a410

    31. Dtxsid901026404

    32. Amy36655

    33. Dimethyl ((2s,2's)-((2s,2's)-2,2'-(5,5'-([1,1'-biphenyl]-4,4'-diyl)bis(1h-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl))dicarbamate

    34. Dimethyl N,n'-(biphenyl-4,4'-diylbis{1h-imidazole-5,2-diyl-((2s)-pyrrolidine-2,1- Diyl)((1s)-1-(1-methylethyl)-2-oxoethane-2,1-diyl)})dicarbamate

    35. Bdbm50387084

    36. Mfcd17129086

    37. S1482

    38. Zinc68204830

    39. Ccg-270425

    40. Cs-0588

    41. Db09102

    42. Ncgc00346533-07

    43. Ncgc00346533-09

    44. Ac-28958

    45. As-75298

    46. Hy-10466

    47. Smr004702917

    48. Sw219754-1

    49. D10065

    50. J-520204

    51. Q5207712

    52. Dimethyl N,n'-((1,1'-biphenyl)-4,4'-diylbis(1h-imidazole-5,2-diyl-((2s)-pyrrolidine-2,1-diyl)((1s)-3-methyl-1-oxobutane-1,2-diyl)))dicarbamate

    53. Methyl ((s)-1-((s)-2-(5-(4'-(2-((s)-1-((methoxycarbonyl)-l-valyl)pyrrolidin-2-yl)-1h-imidazol-5-yl)-[1,1'-biphenyl]-4-yl)-1h-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate

    54. Methyl [(2s)-1-{(2s)-2-[4-(4'-{2-[(2s)-1-{(2s)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-pyrrolidinyl]-1h-imidazol-4-yl}-4-biphenylyl)-1h-imidazol-2-yl]-1-pyrrolidinyl}-3-methyl-1-oxo-2-butanyl]carbamate

    55. Methyl [(2s)-1-{(2s)-2-[4-(4'-{2-[(2s)-1-{(2s)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-1h-imidazol-4-yl}biphenyl-4-yl)-1h-imidazol-2-yl]pyrrolidin-1-yl}-3-methyl-1-oxobutan-2-yl]carbamate

    56. Methyl [(2s)-1-{(2s)-2-[5-(4'-{2-[(2s)-1-{(2s)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-1h-imidazol-5-yl}biphenyl-4-yl)-1h-imidazol-2-yl]pyrrolidin-1-yl}-3-methyl-1-oxobutan-2-yl]carbamate

    57. Methyl N-[(2s)-1-[(2s)-2-[5-(4'-{2-[(2s)-1-[(2s)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl]pyrrolidin-2-yl]-1h-imidazol-5-yl}-[1,1'-biphenyl]-4-yl)-1h-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate

    58. Methyl-n-[(2s)-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2s)-2-(methoxycarbonylamino)-3-methylbutanoyl] Pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1himidazol-2-yl]pyrrolidin-1-yl]3-methyl-1-oxobutan-2-yl]carbamate

    2.4 Create Date
    2009-02-23
    3 Chemical and Physical Properties
    Molecular Weight 738.9 g/mol
    Molecular Formula C40H50N8O6
    XLogP35.1
    Hydrogen Bond Donor Count4
    Hydrogen Bond Acceptor Count8
    Rotatable Bond Count13
    Exact Mass738.38533134 g/mol
    Monoisotopic Mass738.38533134 g/mol
    Topological Polar Surface Area175 Ų
    Heavy Atom Count54
    Formal Charge0
    Complexity1190
    Isotope Atom Count0
    Defined Atom Stereocenter Count4
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Indicated for use with sofosbuvir, with or without ribavirin, for the treatment of chronic HCV genotype 1a/b or 3 infection. The dosing regimen of 60mg daclatasvir 60 mg with 400mg sofosbuvir once a day is recommended for both genontypes. Resistance: Reduced susceptibility to daclatasvir was associated with the polymorphisms at NS5A amino acid positions M28, Q30, L31, and Y93 in genotypes 1a, 1b, and 3a patients. NS5A Resistance Testing is recommended for HCV genotype 1a-infected patients with cirrhosis prior to the initiaition of the treatment, as the risk of resistance development is higher in genotype 1a patients.

    FDA Label

    Daklinza is indicated in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults (see sections 4. 2, 4. 4 and 5. 1).

    For HCV genotype specific activity, see sections 4. 4 and 5. 1.

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    Daclatasvir is a direct-acting antiviral agent that targets the NS5A and causes a decrease in serum HCV RNA levels. It disrupts HCV replication by specifically inhibiting the critical functions of an NS5A protein in the replication complex. It is shown to cause downregulation of the hyperphosphorylation of NS5A. It does not appear to prolong the QT interval even when given at 3 times the maximum recommended dose.

    5.2 FDA Pharmacological Classification
    5.2.1 Active Moiety
    DACLATASVIR
    5.2.2 FDA UNII
    LI2427F9CI
    5.2.3 Pharmacological Classes
    Mechanisms of Action [MoA] - Breast Cancer Resistance Protein Inhibitors
    5.3 ATC Code

    J05AP07

    J - Antiinfectives for systemic use

    J05 - Antivirals for systemic use

    J05A - Direct acting antivirals

    J05AP - Antivirals for treatment of hcv infections

    J05AP07 - Daclatasvir

    5.4 Absorption, Distribution and Excretion

    Absorption

    Studies demonstrated that peak plasma concentrations typically occurred within 2 hours after administration of multiple oral doses ranging from 1 - 100 mg once daily. Steady state is reached after approximately 4 days of once-daily daclatasvir administration. The absolute bioavailability of the tablet formulation is 67%.

    Route of Elimination

    Approximately 88% of total dose of daclatasvir is eliminated into bile and feces in which 53% remains as unchanged form, while 6.6% of the total dose is eliminated primarily unchanged in the urine.

    Volume of Distribution

    The approximate volume of distribution of daclatasvir is 47 L in patients who was orally administered 60 mg tablet followed by 100 g [13C,15N]-daclatasvir intravenously.

    Clearance

    In subjects who received daclatasvir 60 mg tablet orally followed by 100 g radiolabeled daclatasvir intravenously, the total clearance was 4.2 L/h.

    5.5 Metabolism/Metabolites

    Daclastavir is a substrate of CYP3A enzymes where its metabolism is predominantly mediated by CYP3A4 isoform. Oxidative pathways included -oxidation of the pyrrolidine moiety, resulting in ring opening to an aminoaldehyde intermediate followed by an intramolecular reaction between the aldehyde and the proximal imidazole nitrogen atom. High proportion of the drug in the plasma (greater than 97%) is in the unchanged form.

    5.6 Biological Half-Life

    Following multiple dose administration of daclatasvir in HCV-infected subjects, with doses ranging from 1 mg to 100 mg once daily, the terminal elimination half-life of daclatasvir ranged from approximately 12 to 15 hours.

    5.7 Mechanism of Action

    NS5A is a viral nonstructural phospoprotein that is part of a functional replication complex in charge of viral RNA genome amplification on endoplasmic reticulum membranes. It has the ability to bind to HCV RNA. It is shown to have two distinct functions in HCV RNA replication based on phosphorylated states. Maintaining the HCV replication complex is mediated by the cis-acting function of basally phosphorylated NS5A and the trans-acting function of hyperphosphorylated NS5A modulates HCV assembly and infectious particle formation. Daclatasvir is shown to disrupt hyperphosphorylated NS5A proteins thus interfere with the function of new HCV replication complexes. It is also reported that daclatasvir also blocks both intracellular viral RNA synthesis and virion assembly/secretion in vivo.

    API Reference Price

    read-more
    read-more
    [{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1644172200,"product":"DACLATASVIR DIHYDROCHLORIDE","address":"PLOTNO21JAWAHARLAL NEHRU PHARMACIT Y,PARAWADA","city":"VISAKHAPATNAM,ANDHRA PRADESH","supplier":"LAURUS LABS","supplierCountry":"INDIA","foreign_port":"SHEREMETYEVO","customer":"JSC PHARMSTANDARD LEKSREDSTVA","customerCountry":"RUSSIA","quantity":"33.90","actualQuantity":"33.9","unit":"KGS","unitRateFc":"1800","totalValueFC":"59781","currency":"USD","unitRateINR":132182.89085545723,"date":"07-Feb-2022","totalValueINR":"4481000","totalValueInUsd":"59781","indian_port":"HYDERABAD AIR","hs_no":"29349990","bill_no":"8037572","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"PLOTNO21JAWAHARLAL NEHRU PHARMACIT Y,PARAWADA, VISAKHAPATNAM,ANDHRA PRADESH","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1689791400,"product":"DACLATASVIR DIHYDROCHLORIDE (TAX INV NO.","address":"FLAT NO.202, RAJ APARTMENT,RAJEEV NAGAR","city":"HYDERABAD,TELANGANA","supplier":"VIRUPAKSHA ORGANICS","supplierCountry":"INDIA","foreign_port":"ISLAMABAD - ISLAMABA","customer":"MCB BANK LIMITED","customerCountry":"PAKISTAN","quantity":"105.00","actualQuantity":"105","unit":"KGS","unitRateFc":"440","totalValueFC":"45468.1","currency":"USD","unitRateINR":35590.479599999999,"date":"20-Jul-2023","totalValueINR":"3737000.358","totalValueInUsd":"45468.1","indian_port":"HYDERABAD AIR","hs_no":"29332990","bill_no":"0","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"PAKISTAN","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"FLAT NO.202, RAJ APARTMENT,RAJEEV NAGAR, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1705429800,"product":"DACLATASVIR DIHYDROCHLORIDE","address":"FLAT.203,SATYA SAI RESY.PLOT","city":"ROAD,AMEERPET, HYDERABAD,AP","supplier":"NIFTY LABS","supplierCountry":"INDIA","foreign_port":"RIYADH","customer":"CAD MIDDLE EAST PHARMACEUTICAL INDUSTRIES LLC","customerCountry":"SAUDI ARABIA","quantity":"21.00","actualQuantity":"21","unit":"KGS","unitRateFc":"480","totalValueFC":"9923.4","currency":"USD","unitRateINR":39273.857142857145,"date":"17-Jan-2024","totalValueINR":"824751","totalValueInUsd":"9923.4","indian_port":"Hyderabad Air","hs_no":"29332990","bill_no":"6821762","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"SAUDI ARABIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"FLAT.203,SATYA SAI RESY.PLOT, ROAD,AMEERPET, HYDERABAD,AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1712860200,"product":"DACLATASVIR DIHYDROCHLORIDE","address":"2ND FLOOR, SERENE CHAMBERS,","city":"","supplier":"LAURUS LABS","supplierCountry":"INDIA","foreign_port":"SHEREMETYEVO","customer":"JSC PHARMSTANDARD","customerCountry":"RUSSIA","quantity":"60.00","actualQuantity":"60","unit":"KGS","unitRateFc":"1800","totalValueFC":"106577.8","currency":"USD","unitRateINR":148333.74083333332,"date":"12-Apr-2024","totalValueINR":"8900024.45","totalValueInUsd":"106577.8","indian_port":"Hyderabad Air","hs_no":"29349990","bill_no":"9084915","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"2ND FLOOR, SERENE CHAMBERS,, ","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1726857000,"product":"DACLATASVIR DIHYDROCHLORIDE TECHNICAL , CAS NO. 1009119-65-6, BATCH NOS. 41230924001 , 41230924002 MFG DATE S","address":"S. NO. 136\/11,,GAURA VADDO, CALANG","city":"CALANGUTE,GOA","supplier":"SADAR BIOTECH PRIVATE ","supplierCountry":"INDIA","foreign_port":"MOSCOW","customer":"TO THE ORDER","customerCountry":"RUSSIA","quantity":"129.00","actualQuantity":"129","unit":"KGS","unitRateFc":"99396","totalValueFC":"153005.9","currency":"INR","unitRateINR":99396.001705426359,"date":"21-Sep-2024","totalValueINR":"12822084.22","totalValueInUsd":"153005.9","indian_port":"Bombay Air","hs_no":"29420090","bill_no":"4235089","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"S. NO. 136\/11,,GAURA VADDO, CALANG, CALANGUTE,GOA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1727029800,"product":"DACLATASVIR DIHYDROCHLORIDE TECHNICAL","address":"S. NO. 136\/11,,GAURA VADDO, CALANG","city":"CALANGUTE,GOA","supplier":"SADAR BIOTECH PRIVATE ","supplierCountry":"INDIA","foreign_port":"MOSCOW","customer":"TO THE ORDER ,","customerCountry":"RUSSIA","quantity":"129.00","actualQuantity":"129","unit":"KGS","unitRateFc":"99396","totalValueFC":"153005.9","currency":"INR","unitRateINR":99396.001705426359,"date":"23-Sep-2024","totalValueINR":"12822084.22","totalValueInUsd":"153005.9","indian_port":"Bombay Air","hs_no":"29420090","bill_no":"4275880","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"S. NO. 136\/11,,GAURA VADDO, CALANG, CALANGUTE,GOA","customerAddress":""},{"dataSource":"API Import","activeIngredients":"DACLATASVIR DIHYDROCHLORIDE","year":"2021","qtr":"Q1","strtotime":1609439400,"product":"DACLATASVIR DIHYDROCHLORIDE","address":"26, MANOJ INDUSTRIAL ESTATE,G.D. AMBEKAR MARG, WADALA","city":"MUMBAI, MAHARASHTRA","supplier":"HANGZHOU YAXIN PHARMACEUTICAL ","supplierCountry":"CHINA","foreign_port":"SHANGHAI","customer":"FREDUN PHARMACEUTICALS LTD.","customerCountry":"INDIA","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"700","totalValueFC":"712.6","currency":"USD","unitRateINR":"52115","date":"01-Jan-2021","totalValueINR":"52115","totalValueInUsd":"712.6","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"2200067","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI","supplierAddress":"","customerAddress":"26, MANOJ INDUSTRIAL ESTATE,G.D. AMBEKAR MARG, WADALA"}]
    01-Jan-2021
    23-Sep-2024
    KGS
    overview
    Loading...

    Average Price (USD/KGS)

    Number of Transactions

    Total Quantity (KGS)

    Total Value (USD)

    Quantity (KGS) & Unit rate (USD/KGS) over time

    API Imports and Exports

    Importing Country Total Quantity
    (KGS)    		 Average Price
    (USD/KGS)    		 Number of Transactions

    Upgrade, download data, analyse, strategize, subscribe with us contact

    DRUG PRODUCT COMPOSITIONS

    Do you need Business Intel? Ask us

    DOSAGE - TABLET;ORAL - EQ 30MG BASE

    USFDA APPLICATION NUMBER - 206843

    read-more

    DOSAGE - TABLET;ORAL - EQ 60MG BASE

    USFDA APPLICATION NUMBER - 206843

    read-more

    DOSAGE - TABLET;ORAL - EQ 90MG BASE

    USFDA APPLICATION NUMBER - 206843

    read-more

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Coating Systems & Additives

    read-more
    read-more

    Fillers, Diluents & Binders

    read-more
    read-more

    Controlled & Modified Release

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Lubricants & Glidants

    read-more
    read-more

    Granulation

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    Empty Capsules

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    Rheology Modifiers

    read-more
    read-more

    Vegetarian Capsules

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Coloring Agents

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Topical

    read-more
    read-more

    Parenteral

    read-more
    read-more

    Surfactant & Foaming Agents

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search